Kim, YevgeniyKim, AlekseiSharip, AinurSharip, AigulJiang, JuhongYang, QingXie, Yingqiu2017-11-142017-11-142017-02-17Kim Yevgeniy et al.(>6), 2017(February 17), Reverse the Resistance to PARP Inhibitors, International Journal of Biological Sciences, vol.13, pp.98-208doi: 10.7150/ijbs.17240http://nur.nu.edu.kz/handle/123456789/2800One of the DNA repair machineries is activated by Poly (ADP-ribose) Polymerase (PARP) enzyme. Particularly, this enzyme is involved in repair of damages to single-strand DNA, thus decreasing the chances of generating double-strand breaks in the genome. Therefore, the concept to block PARP enzymes by PARP inhibitor (PARPi) was appreciated in cancer treatment. PARPi has been designed and tested for many years and became a potential supplement for the conventional chemotherapy. However, increasing evidence indicates the appearance of the resistance to this treatment. Specifically, cancer cells may acquire new mutations or events that overcome the positive effect of these drugs. This paper describes several molecular mechanisms of PARPi resistance which were reported most recently, and summarizes some strategies to reverse this type of drug resistance.enOpen Access - the content is available to the general publicAttribution-NonCommercial-ShareAlike 3.0 United StatesPARPPARP inhibitordrug resistanceDNA repairResearch Subject Categories::NATURAL SCIENCES::BiologyArticle